Oral Iron Chelator Deferasirox in the Treatment of Secondary Hemochromatosis following Bone Marrow Transplantation in a Patient with Severe Aplastic Anemia

Publisher： Karger

E-ISSN： 1421-9662|125|4|219-221

ISSN： 0001-5792

Source： Acta Haematologica, Vol.125, Iss.4, 2011-01, pp. : 219-221

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Results of Bone Marrow Transplantation in Patients with Acquired Severe Aplastic Anemia

By  

Acta Haematologica, Vol. 103, Iss. 1, 2000-03 ,pp. : 19-25

Karger

Access to resources Recommend Favorite

Aplastic Anemia before Bone Marrow Transplantation and Antilymphocyte Globulin

By  

Acta Haematologica, Vol. 103, Iss. 1, 2000-03 ,pp. : 11-15

Karger

Access to resources Recommend Favorite

Deferasirox: a novel, once-daily oral iron chelator

By Cappellini Maria Domenica  

Therapy, Vol. 3, Iss. 4, 2006-07 ,pp. : 453-460

Future Medicine

Access to resources Recommend Favorite

The oral iron chelator deferasirox inhibits NF‐κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 576-582

John Wiley & Sons Inc

Access to resources Recommend Favorite

Iron Chelation with Deferasirox in Two Patients with HFE Hemochromatosis and Chronic Anemia

By  

Acta Haematologica, Vol. 126, Iss. 2, 2011-06 ,pp. : 119-121

Karger

Access to resources Recommend Favorite